Status:
UNKNOWN
Dose Finding Study of Remimazolam for Laryngeal Mask Airway Insertion
Lead Sponsor:
Yonsei University
Conditions:
Orthopedic Surgery
Eligibility:
All Genders
19-65 years
Phase:
NA
Brief Summary
Laryngeal mask airways (LMA) are widely used in patients receiving general anesthesia and are known to have the following advantages over the endotracheal tube: lower incidence of postoperative sore t...
Eligibility Criteria
Inclusion
- Adult patients aged 19\~65 year
- ASA class I\~III
- Patients scheduled for orthopedic surgery under general anesthesia and eligible for LMA use.
Exclusion
- Patient refusal
- Patients unable to read consent form
- Anticipated difficult mask ventilation
- Active URI or uncontrolled asthma
- Pneumonia
- Risk of aspiration such as GERD
- History of allergies to benzodiazepines
- Decreased liver or kidney function
- Pregnant or breastfeeding patients
- BMI \> 30kg/m2
- History of substance abuse/addiction
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 27 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT05298228
Start Date
March 1 2022
End Date
July 27 2023
Last Update
March 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Health System, Severance Hospital
Seoul, South Korea